Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease
Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.
- Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.
- ALZ-801/valiltramiprosate is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
- In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid oligomers at the Phase 3 clinical dose.
- “Given these encouraging results, we are compelled to extend the trial for an additional year, bringing the treatment period to four years for these patients.